Dehydroepiandrosterone treatment of midlife dysthymia
Dehydroepiandrosterone treatment of midlife dysthymia
复制标题
DOI：
10.1016/s0006-3223(99)00066-9
复制
发表时间：
1999-06-15
影响因子：
10.6
通讯作者：
Rubinow, DR
中科院分区：
文献类型：
--
作者：
Bloch, M;Schmidt, PJ;Rubinow, DR
背景资料：本研究评估的疗效肾上腺雄激素，脱氢表雄酮，在治疗中年发病的恶劣心境mythmia.Methods：一个双盲，随机交叉治疗研究如下：3周90毫克脱氢表雄酮，3周450毫克脱氢表雄酮，6周安慰剂。结果指标包括以下内容。横断面自我评定包括贝克抑郁量表和视觉模拟症状量表。横断面客观评分包括汉密尔顿抑郁量表、康奈尔心境恶劣量表和认知测试组合。17名年龄在45至63岁之间的中年发病的心境恶劣的男性和女性参加了这项研究。对脱氢表雄酮或安慰剂的反应被定义为从基线的汉密尔顿抑郁评定量表或贝克抑郁inventory.Results：在15例完成研究的患者中，脱氢表雄酮对情绪的强大影响与安慰剂相比，观察到50%的减少。60%的患者在6周治疗期结束时对脱氢表雄酮有反应，而安慰剂组为20%。每天90 mg治疗3周后观察到显著反应，改善最显著的症状是快感缺乏、能量丧失、缺乏动力、情感“麻木”、悲伤、无法科普和担忧。脱氢表雄酮对认知功能或睡眠障碍没有特异性影响，尽管不能排除II型错误。结论：这项试点研究表明，脱氢表雄酮是一种有效的治疗中年发病的心境恶劣。
Background: This study evaluated the efficacy of the adrenal androgen, dehydroepiandrosterone, in the treatment of midlife-onset dysthymia.Methods: A double-blind, randomized crossover treatment study was performed as follows: 3 weeks on 90 mg dehydroepiandrosterone, 3 weeks on 450 mg dehydroepiandrosterone, and 6 weeks on placebo. Outcome measures consisted of the following. Cross-sectional self-ratings included the Beck Depression Inventory, and visual analogue symptom scales. Cross-sectional objective ratings included the Hamilton Depression Rating Scale, the Cornell Dysthymia Scale and a cognitive test battery. Seventeen men and women aged 45 to 63 years with midlife-onset dysthymia participated in this study. Response to dehydroepiandrosterone or placebo was defined as a 50% reduction from baseline in either the Hamilton Depression Rating Scale or the Beck Depression Inventory.Results: In 15 patients who completed the study, a robust effect of dehydroepiandrosterone on mood was observed compared with placebo. Sixty percent of the patients responded to dehydroepiandrosterone at the end of the 6-week treatment period compared with 20% on placebo. A significant response was seen after 3 weeks of treatment on 90 mg per day, The symptoms that improved most significantly were anhedonia, loss of energy, lack of motivation, emotional "numbness," sadness, inability to cope, and worry. Dehydroepiandrosterone showed no specific effects on cognitive function or sleep disturbance, although a type II error could not be ruled out.Conclusions: This pilot study suggests that dehydroepiandrosterone is an effective treatment for midlife-onset dysthymia.